Abstract
Some antimalarial agents in use typically bear basic side chains as ligands. Such ligands were attached to the amino substituent of a bridgehead atom of already antiprotozoal active 3-azabicyclo[3.2.2]nonanes. Structure verification was done by NMR measurements. The new compounds were tested for their antiplasmodial and antitrypanosomal activities against Plasmodium falciparum K 1 (multiresistant) and Trypanosoma brucei rhodesiense as well as for their cytotoxicity against L6 cells. Their activities are compared to those of already prepared compounds and structure–activity relationships are discussed.
Similar content being viewed by others
References
Attaran, A., K.I. Barnes, C. Curtis, U. d’Allesandro, C.I. Fanello, M.R. Galinski, G. Kowaro, S. Looareesuwan, M. Makanga, T.K. Mutabingwa, A. Talisuna, J.F. Trape, and W.M. Watkins. 2004. WHO, the Global Fund, and a medical malpractice in malaria treatment. Lancet 363: 237–240.
Berger, H., W. Seebacher, R. Saf, M. Kaiser, R. Brun, and R. Weis. 2006. Antiprotozoal activities of new bis-chlorophenyl derivatives of bicyclic octanes and aza-nonanes. Bioorganic & Medicinal Chemistry Letters 16: 5457–5461.
Box, K.J., and J. Comer. 2008. Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class. Current Drug Metabolism 9: 869–878.
Brun, R., J. Blum, F. Chappuis, and C. Burri. 2010. Human African trypanosomiasis. Lancet 375: 148–159.
Bytheway, I., M.G. Darley, and Paul L.A. Popelier. 2008. The calculation of polar surface area from first principles: An application of quantum chemical topology to drug design. ChemMedChem 3: 445–453.
Dahan, A., J.M. Miller, and G.L. Amidon. 2009. Prediction of solubility and permeability class membership: Provisional BCS classification of the world’s top oral drugs. AAPS Journal 11: 740–746.
Dahan, A., O. Wolk, Y.H. Kim, C. Ramachandran, G.M. Crippen, T. Takagi, M. Bermejo, and G.L. Amidon. 2013. Purely in silico BCS classification: Science based quality standards for the World’s drugs. Molecular Pharmaceutics 10: 4378–4390.
Dhanda, S.K., D. Singla, A.K. Mondal, and G.P. Raghava. 2013. DrugMint: A webserver for predicting and designing of drug-like molecules. Biology Direct 8: 28.
Gillespie, D., M. Claeson, H. Mshinda, H. Troedsson, and C.G. Victoria. 2003. Knowledge in action for child survival. Lancet 362: 323–327.
Kennedy, P.G.E. 2006. Diagnostic and neuropathogenesis issues in human African trypanosomiasis. International Journal for Parasitology 36: 505–512.
Lajiness, M.S., M. Vieth, and J. Erickson. 2004. Molecular properties that influence oral drug-like behavior. Current Opinion in Drug Discovery & Development 7: 470–477.
Lim, P., A.P. Alker, N. Khim, N.K. Shah, S. Incardona, S. Doung, P. Yi, D.M. Bouth, C. Bouchier, O.M. Puijalon, S.R. Meshnik, C. Wongsrichanalai, T. Fandeur, J. Le Bras, P. Ringwald, and F. Ariey. 2009. Pfmrd1 copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. Malaria Journal 8: 11. doi:10.1186/1475-2875-8-11.
Lipinski, C.A., F. Lombardo, B.W. Dominy, and P.J. Feeney. 2012. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 64: 4–17.
Loutan, L. 2003. Malaria: Still a threat to travellers. International Journal of Antimicrobial Agents 21: 158–163.
Mohsin, N.A., W. Seebacher, J. Faist, F. Belaj, R. Saf, M. Kaiser, R. Brun, and R. Weis. 2014. Synthesis of antiprotozoal diamines by regioselective insertion of nitrogen into a bicyclic ring system. Monatshefte fuer Chemie 145: 1319–1327.
Pajouhesh, H., and G.R. Lenz. 2005. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2: 541–553.
Seebacher, W., and R. Weis. 2011. Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives. Int. Patent, WO 2011/035355 A1.
Seebacher, W., R. Brun, R. Saf, D. Kröpfl, and R. Weis. 2004. New derivatives of 4-aminobicyclo [2.2.2]octanones and -ols as potential asntiprotozoals. Monatshefte fuer Chemie 135: 313–322.
Seebacher, W., M. Kaiser, R. Brun, R. Saf, and R. Weis. 2005. 4-Aminobicyclo[2.2.2]octan-2-ones and -ols via enamine intermediates. Monatshefte fuer Chemie 136: 625–634.
Seebacher, W., and R. Weis, R. 2011. Novel antimalarial 3-azabicyclo[3.2.2]nonane derivatives. Int. Patent, WO 2011/035355 A1.
Sushko, I., S. Novotarskyi, R. Koerner, A.K. Pandey, M. Rupp, W. Teetz, S. Brandmaier, A. Abdelaziz, V.V. Prokopenko, V.Y. Tanchuk, R. Todeschini, A. Varnek, G. Marcou, P. Ertl, V. Potemkin, M. Grishina, et al. 2011. Online chemical modeling environment (OCHEM): Web platform for data storage, model development and publishing of chemical information. Journal of Computer-Aided Molecular Design 25: 533–554.
Steinhilber, D., M. Schubert-Zsilavec, and M.J. Roth. 2010. Medizinische Chemie, 2nd ed. Stuttgart: Deutscher Apotheker Verlag.
van de Waterbeemd, H. 2008. Physicochemical approaches to drug absorption. In Drug bioavailability, ed. R. Mannhold, H. Kubinyi, G. Folkers, H. van de Waterbeemd, and B. Testa, 69–99. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.
Veber, D.F., S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple. 2002. Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry 45: 2615–2623.
Weis, R., K. Schweiger, W. Seebacher, and F. Belaj. 1998. One-pot synthesis of 4-aminobicyc-lo[2.2.2]octan-2-ones. Tetrahedron 54: 14015–14022.
Weis, R., H. Berger, M. Kaiser, R. Brun, R. Saf, and W. Seebacher. 2008. Synthesis of bicyclic amines and their activities against Trypanosoma brucei rhodesiense and Plasmodium falciparum K1. Archives of Pharmacal Research 31: 688–697.
Acknowledgments
This work was supported by a research Grant of the Karl-Franzens-University of Graz.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ahmad, S., Seebacher, W., Wolkinger, V. et al. Synthesis and antiprotozoal activities of new 3-azabicyclo[3.2.2]nonanes. Arch. Pharm. Res. 38, 1455–1467 (2015). https://doi.org/10.1007/s12272-014-0523-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-014-0523-1